Skip to main content

Advertisement

SpringerLink
Log in

Modern Multidisciplinary Management of Brain Metastases

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Ideal management of brain metastases (BMs) requires simultaneous control of the existing brain metastasis (local brain control), prevention of future BMs (distant brain control), and control of the systemic cancer (systemic control). Available tools include whole brain radiation therapy (WBRT), surgery, stereotactic radiosurgery (SRS), and systemic therapies, such as chemotherapies, biologic agents, and radiosensitizing agents. Selecting the combination of these tools is highly individualized and is impacted by numerous factors involving the tumor, patient, provider, and evolving evidence. Historically, patients received WBRT, either alone or with local treatments (surgery or SRS). However, concern about the effects of WBRT, coupled with improvements in local control and survival in select patients, with the combination treatment, has led to a reconsideration of the role of WBRT. Additionally, there have been advancements in the efficacy and tolerance of systemic therapies and clarification regarding the relative risks and symptoms of tumor recurrence versus treatment complications. Thankfully, individualizing modern multidisciplinary management for patients with BMs is being aided by numerous recently completed, ongoing, and planned prospective series.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Shaffrey ME, Mut M, Asher AL, et al.: Brain metastases. Curr Probl Surg 2004, 41:665–741.

    Article  PubMed  Google Scholar 

  2. Norden AD, Wen PY, Kesari S: Brain metastases. Curr Opin Neurol 2005, 18:654–661.

    PubMed  Google Scholar 

  3. Brem SN, Nabors LB, Raizer JJ: Central nervous system cancers. National Comprehensive Cancer Guidelines. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed November 2009.

  4. Sanoff HK, Sargent DJ, Campbell ME, et al.: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008, 26:5721–5727.

    Article  CAS  PubMed  Google Scholar 

  5. Mongan JP, Fadul CE, Cole BF, et al.: Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer 2009, 8: 100–105.

    Article  CAS  Google Scholar 

  6. Gori S, Rimondini S, De Angelis V, et al.: Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007, 12:766–773.

    Article  PubMed  Google Scholar 

  7. Fortin D, Gendron C, Boudrias M, et al.: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer 2007, 109:751–760.

    Article  CAS  PubMed  Google Scholar 

  8. Long DM, Winer EP: Capillary ultrastructure in human metastatic brain tumors. J Neurosurg 1979, 51:53–58.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang RD, Price JE, Fujimaki T, et al.: Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 1992, 141:1115–1124.

    CAS  PubMed  Google Scholar 

  10. Jain RK, Tong RT, Munn LL: Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007, 67:2729–2735.

    Article  CAS  PubMed  Google Scholar 

  11. Donelli MG, Zucchetti M, D'Incalci M: Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992, 30:251–260.

    Article  CAS  PubMed  Google Scholar 

  12. Moscetti L, Nelli F, Felici A, et al.: Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer 2007, 109:274–281.

    Article  CAS  PubMed  Google Scholar 

  13. Gaspar L, Scott C, Rotman M, et al.: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745–751.

    CAS  PubMed  Google Scholar 

  14. Sperduto PW, Berkey B, Gaspar LE, et al.: A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008, 70:510–514.

    PubMed  Google Scholar 

  15. Wen PY, Loeffler JS (1999) Management of brain metastases. Oncology (Williston Park). 13:941–954, 957–961; discussion 961–962, 969

    CAS  Google Scholar 

  16. Koehler PJ: Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995, 6:19–33.

    Article  CAS  PubMed  Google Scholar 

  17. Chuba PJ, Aronin P, Bhambhani K, et al.: Hyperbaric oxygen therapy for radiation-induced brain injury in children. Cancer 1997, 80:2005–2012.

    Article  CAS  PubMed  Google Scholar 

  18. Gonzalez J, Kumar AJ, Conrad CA, et al.: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007, 67:323–326.

    CAS  PubMed  Google Scholar 

  19. Ruben JD, Dally M, Bailey M, et al.: Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65:499–508.

    PubMed  Google Scholar 

  20. Sirven JI, Wingerchuk DM, Drazkowski JF, et al.: Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004, 79:1489–1494.

    Article  PubMed  Google Scholar 

  21. Tremont-Lukats IW, Ratilal BO, Armstrong T, et al.: Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008:CD004424.

  22. Cairncross JG, Kim JH, Posner JB: Radiation therapy for brain metastases. Ann Neurol 1980, 7:529–541.

    Article  CAS  PubMed  Google Scholar 

  23. Nieder C, Berberich W, Schnabel K: Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys 1997, 39:25–30.

    CAS  PubMed  Google Scholar 

  24. Schiff D, Cavaliere R: Role of fractionated radiotherapy and radiotherapy in newly diagnosed brain metastases. In ASCO Educational Book. Edited by Govindan R. Alexandria, VA: American Society of Clinical Oncology; 2009:95–99.

    Google Scholar 

  25. Sawaya R, Hammoud M, Schoppa D, et al. (1998) Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery, 42:1044–1055; discussion 1055–1056.

    Article  CAS  PubMed  Google Scholar 

  26. Mueller R, Soffietti R, Abaciouglu MU, et al.: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1–3 cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2009, 27:89s. This article discusses the long-awaited prospective results on the combination of WBRT with local treatment (surgery or SRS), including their impact on local control, neurologic symptoms, survival, and NCF.

  27. Patchell RA, Tibbs PA, Regine WF, et al.: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485–1489.

    Article  CAS  PubMed  Google Scholar 

  28. Andrews DW, Scott CB, Sperduto PW, et al.: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665–1672.

    Article  PubMed  Google Scholar 

  29. Swinson BM, Friedman WA: Linear accelerator stereotactic radiosurgery for metastatic brain tumors: 17 years of experience at the University of Florida. Neurosurgery 2008, 62:1018–1031; discussion 1031–1032. This article represents one of the largest and robust prospective datasets involving SRS for BMs.

    Article  PubMed  Google Scholar 

  30. Sawrie SM, Guthrie BL, Spencer SA, et al.: Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys 2008, 70:181–186.

    PubMed  Google Scholar 

  31. Patchell RA, Tibbs PA, Walsh JW, et al.: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494–500.

    Article  CAS  PubMed  Google Scholar 

  32. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al.: Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993, 33:583–590.

    Article  CAS  PubMed  Google Scholar 

  33. Mintz AH, Kestle J, Rathbone MP, et al.: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996, 78:1470–1476.

    Article  CAS  PubMed  Google Scholar 

  34. Aoyama H, Shirato H, Tago M, et al.: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295:2483–2491.

    Article  CAS  PubMed  Google Scholar 

  35. Chang EL, Wefel JS, Maor MH, et al.: A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007, 60:277–283; discussion 283–284.

    Google Scholar 

  36. Meyers CA, Smith JA, Bezjak A, et al.: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004, 22:157–165.

    Article  CAS  PubMed  Google Scholar 

  37. Gerstner ER, Fine RL: Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007, 25:2306–2312.

    Article  PubMed  Google Scholar 

  38. Kim KH, Lee J, Lee JI, et al.: Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? Lung Cancer 2009 Jul 8 (Epub ahead of print).

  39. Rohr U, Augustus S, Lasserre SF, et al.: Safety of bevacizumab in patients with metastases to the central nervous system [abstract]. J Clin Oncol 2009, 27:88s.

    Google Scholar 

  40. Socinski MA, Langer CJ, Huang JE, et al.: Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009, 27:5255–5261.

    Article  CAS  PubMed  Google Scholar 

  41. Antonadou D, Paraskevaidis M, Sarris G, et al.: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002, 20:3644–3650.

    Article  CAS  PubMed  Google Scholar 

  42. Verger E, Gil M, Yaya R, et al.: Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005, 61:185–191.

    CAS  PubMed  Google Scholar 

  43. Addeo R, De Rosa C, Faiola V, et al.: Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 2008, 113:2524–2531.

    Article  CAS  PubMed  Google Scholar 

  44. Neuhaus T, Ko Y, Muller RP, et al.: A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 2009, 100:291–297.

    Article  CAS  PubMed  Google Scholar 

  45. Fiveash JB: A phase II study of radiosurgery and temozolomide for patients with one to four brain metastases. J Clin Oncol 2007, 25:2048.

    Google Scholar 

  46. Dunbar E, Murad G, Keeling C: Study of temozolomide to treat newly diagnosed brain metastases [NCT00717275]. Available at http://clinicaltrials.gov/ct2/show/NCT00717275?term=erin+dunbar&rank=5. Accessed October 2009.

  47. Ma S, Xu Y, Deng Q, et al.: Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 2009, 65:198–203.

    Article  PubMed  Google Scholar 

  48. Richards GM, Khuntia D, Mehta MP: Therapeutic management of metastatic brain tumors. Crit Rev Oncol Hematol 2007, 61:70–78.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Preston A. Wells Jr Center for Brain Tumor Therapy, University of Florida, 100 South Newell Drive, McKnight Brain Institute, Gainesville, FL, 32610, USA

    Erin M. Dunbar

  2. Department of Medicine, Division of Hematology-Oncology, 1600 S. Archer Rd, Gainesville, FL, 32610, USA

    Sajeve S. Thomas

Authors
  1. Sajeve S. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erin M. Dunbar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erin M. Dunbar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas, S.S., Dunbar, E.M. Modern Multidisciplinary Management of Brain Metastases. Curr Oncol Rep 12, 34–40 (2010). https://doi.org/10.1007/s11912-009-0073-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-009-0073-8

Keywords

Search

Navigation